GlassScriptPhysician profile
Surendra S Shah
NPI 1104829928
$2,450.72
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,988 · 2020: $403 · 2021: $59.93.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $417.90 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $353.86 | 2019-2020 | |
| Genentech USA, INC. | $280.91 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $252.05 | 2019-2021 | |
| Janssen Biotech, INC. | $177.83 | 2019 | |
| Novartis Pharmaceuticals Corporation | $109.34 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $93.72 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $87.25 | 2019-2020 | |
| Pfizer INC. | $67.67 | 2019 | |
| Genzyme Corporation | $63.17 | 2019 | |
| Foundation Medicine, INC. | $58.35 | 2019 | |
| Eisai INC. | $56.86 | 2019 | |
| Rigel Pharmaceuticals, INC. | $48.67 | 2019 | |
| Seagen INC. | $39.73 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $38.85 | 2019-2020 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Helsinn Therapeutics (U.S.), INC. | $37.34 | 2019 | |
| Daiichi Sankyo INC. | $34.19 | 2019 | |
| Amgen INC. | $33.17 | 2019 | |
| Incyte Corporation | $30.89 | 2019-2020 | |
| Gilead Sciences, INC. | $26.56 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $26.47 | 2019 | |
| Celgene Corporation | $24.38 | 2020 | |
| Exelixis INC. | $23.11 | 2019 | |
| Amag Pharmaceuticals, INC. | $20.54 | 2020 | |
| Pharmacyclics LLC, An Abbvie Company | $20.40 | 2020 | |
| Ipsen Biopharmaceuticals, INC | $14.59 | 2019 | |
| Lilly USA, LLC | $12.92 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Surendra Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.